MHRA backs Merck’s MET inhibitor Tepmetko
Conditional marketing authorisation granted for patients with advanced NSCLC with METex14 skipping alterations
Read More
Tag: MET inhibitor
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
